Thrombotic thrombocytopenic purpura: Crossing to safety
Corresponding Author
James N. George MD
Department of Biostatistics & Epidemiology, Hudson College of Public Health, Hematology-Oncology Section, Department of Medicine, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
Correspondence
James N. George, Hematology-Oncology Section, Department of Medicine, College of Medicine, Department of Biostatistics & Epidemiology, Hudson College of Public Health, The University of Oklahoma Health Sciences Center, 801 NE 13th Street, Oklahoma City, OK 73104, USA.
Email: [email protected]
Search for more papers by this authorCorresponding Author
James N. George MD
Department of Biostatistics & Epidemiology, Hudson College of Public Health, Hematology-Oncology Section, Department of Medicine, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
Correspondence
James N. George, Hematology-Oncology Section, Department of Medicine, College of Medicine, Department of Biostatistics & Epidemiology, Hudson College of Public Health, The University of Oklahoma Health Sciences Center, 801 NE 13th Street, Oklahoma City, OK 73104, USA.
Email: [email protected]
Search for more papers by this author
REFERENCES
- 1Fuchs WE, George JN, Dotin LN, Sears DA. Thrombotic thrombocytopenic purpura. Occurrence two years apart during late pregnancy in two sisters. JAMA. 1976; 235(19): 2126.
- 2Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine. 1966; 45(2): 139–59.
- 3Coppo P, Bubenheim M, Azoulay E, Galicier L, Malot S, Bigé N, et al. A regimen with caplacizumab, immunosuppression and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood. 2021; 137(6): 733–42.
- 4Bukowski RM, Hewlett JS, Harris JW, Hoffman GC, Battle JD Jr, Silverblatt E, Yang I-Y. Exchange transfusions in the treatment of thrombotic thrombocytopenic purpura. Semin Hematol. 1976; 13: 219–32.
- 5Rubenstein MA, Kagan EM, MacGillviray MH, Merliss R, Sacks H. Unusual remission in a case of thrombotic thrombocytopenic purpura syndrome following fresh blood exchange transfusion. Ann Intern Med. 1959; 51: 1409–19.
- 6Bukowski RM, King JW, Hewlett JS. Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura. Blood. 1977; 50: 413–7.
- 7Byrnes JJ, Khurana M. Treatment of thrombotic thrombocytopenic purpura with plasma. N Engl J Med. 1977; 297: 1386–9.
- 8Upshaw JDJ. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med. 1978; 298(24): 1350–2.
- 9Okuno T, Kosova L. Plasmapheresis for thrombotic thorombocytopenic purpura (TTP). Transfusion. 1979; 19(3): 342–4.
- 10Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med. 1991; 325(6): 393–7.
- 11Clark WF, Garg AX, Blake PG, et al. Effect of awareness of a randomized controlled trial on use of experimental therapy. JAMA. 2003; 290(10): 1351–5.
- 12Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura - hemolytic uremic syndrome. N Engl J Med. 1991; 325(6): 398–403.
- 13Lim W, Vesely SK, George JN. The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. Blood. 2015; 125(10): 1526–31.
- 14Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016; 374(6): 511–22.
